Introduction
Molecular markers are useful tools for early detection, prediction of prognosis and monitoring of targeted therapy for individual cancer patients. For patients with non-small-cell lung cancer (NSCLC), which accounts for 25% of all cancer deaths worldwide and continues to increase in frequency, 1 -3 no clinically reliable molecular markers are currently available. We reported previously that the seven genes AKR1B10, CBLC, CYP24A1, ALDH3A1, S100P, PLUNC and LOC147166 were potential diagnostic markers for NSCLC when assessed in bioinformatic analyses of publicly available gene expression data. 4 Over-expression of AKR1B10, which codes for the aldo-keto reductase family 1 member B10 protein (AKR1B10), has been reported to be related to the progression of various cancers, such as hepatocellular carcinoma, AKR1B10 as a prognostic biomarker for NSCLC NSCLC, breast cancer, oral squamous cell carcinoma, colorectal cancer and cervical cancer. 5 -12 AKR1B10 is an essential enzyme in the metabolism of retinoic acid. 5 Upregulated transcription of associated intracellular reactive carbonyls causes changes in the reduction pathway of the aldehyde and ketone, 13, 14 which affects the biological process and leads to aberrant cell proliferation and differentiation owing to retinoic acid depletion. 15, 16 In this study the relationship between the level of expression of AKR1B10 mRNA and clinical factors, such as age, sex, smoking status and various tumour characteristics, was analysed to assess the validity of AKR1B10 as a molecular marker for NSCLC.
Patients and methods

PATIENT POPULATION AND SAMPLE SELECTION
Eligible patients were those who underwent resection of primary NSCLC with intent to cure between January 1995 and December 2007 in the Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea. Patients who had received pre-operative neoadjuvant treatments and patients with double primary lung cancers were excluded. Patients from whom tissue had been removed and were found to have benign or inflammatory lung disease were used as controls.
Experienced pathologists immediately examined all surgically removed lung tumour tissues. One or two tissue samples from the NSCLC patients were removed from the periphery of each mass (avoiding necrotic regions) and were immediately frozen at -80°C. Samples of adjacent nonmalignant lung tissue (> 5 cm from the edge of the tumour) were taken from the same NSCLC patients and frozen.
The medical records (including smoking status defined as 'smoker' [current or exsmoker] or 'never smoker') frozen samples and haematoxylin and eosin slides (see next section) for all the specimens were reviewed by one pathologist for suitability for use in the study. Only tumour samples that conformed to the World Health Organization's histopathological criteria for adenocarcinoma or squamous cell carcinoma and that had > 70% tumour cell content were included.
The study was approved by the Institutional Review Board of the Samsung Medical Centre, Sungkyunkwan University School of Medicine and all patients gave their written informed consent before they were included.
TISSUE PREPARATION AND RNA EXTRACTION
Suitable frozen tumour tissues underwent microdissection. Briefly, frozen tissue was lightly stained with haematoxylin and eosin to improve visualization, and necrotic and normal tissues were removed. Each of the microdissected tumour samples was placed in 1 ml easy-Blue™ reagent from a commercially available RNA isolation kit (EasySpin™ Total RNA Extraction Kit; iNtRON Biotechnology, Gyeonggi-Do, Korea) and immediately homogenized by vortexing for extraction of total RNA. The quantity and quality of RNA were analysed by spectrometry and use of an Agilent 2100 Bioanalyzer and Agilent RNA 6000 Nano Kit (Agilent Technologies Inc., Waldbronn, Germany).
QUANTITATIVE RT-PCR
Quantitative real-time reverse transcriptionpolymerase chain reaction (RT-PCR) was used to measure levels of AKR1B10 mRNA in the samples relative to glyceraldehyde phosphate dehydrogenase (GAPDH) as the AKR1B10 as a prognostic biomarker for NSCLC internal control gene.
The RNA was reversed transcribed to obtain cDNA for AKR1B10 and the internal control gene using a mixture of oligodeoxythymidine and random primers (Transcriptor First Strand cDNA Synthesis Kit; Roche, Mannheim, Germany). FAM TM dyelabelled TaqMan ® MGB probes (Applied Biosystems, Foster City, CA, USA) were used that were specific for the AKR1B10 gene and internal control gene. The PCR reaction mixture consisted of the RT product, TaqMan ® 2× Universal PCR Master Mix (Applied Biosystems) and the appropriate 20× TaqMan ® gene expression assay mix (Applied Biosystems) containing primers and probes for AKR1B10 and the internal control gene. Cycling parameters were an initial 50°C for 2 min (uracil-DNA-glycosylase activation) and 95°C for 10 min, followed by 40 cycles of denaturing at 95°C for 15 s and reannealing at 60°C for 60 s, and then a final extension step at 60°C for 60 s. All reactions were run in triplicate.
Relative expression of the gene compared with the internal control gene was analysed according to the comparative CT method using the equation 2 -∆∆CT , where ∆∆CT = CT (target gene) -CT (internal control gene).
STATISTICAL ANALYSES
Results are presented as mean ± SD for continuous variables and as number and percentage for categorical variables. Statistical analyses were performed with SAS ® statistical software version 9.1 (SAS Institute, Cary, NC, USA). Differences in AKR1B10 mRNA expression for the various clinical and pathological variables were compared with the two-tailed unpaired Student's t-test, non-parametric analysis of variance and Wilcoxon's two-sample test, as appropriate. Multiple regression analysis was used to identify those factors associated with AKR1B10 mRNA expression in NSCLC. Age, gender, smoking status, tumour cell type, cell differentiation, primary tumour category, lymph node involvement, primary tumour stage, tumour size and recurrence status were used as independent variables, with AKR1B10 mRNA expression as the dependent variable. Correlations between AKR1B10 mRNA expression and smoking and gender were investigated. All statistical tests were two-sided and differences were deemed significant when P < 0.05.
Results
PATIENTS AND SAMPLES
Frozen tumour tissues were collected from 818 of the 2523 patients who underwent resection of primary NSCLC with intent to cure between January 1995 and December 2007 in the Samsung Medical Centre. Tumour samples from 615 of these patients were selected for RNA extraction. After rejecting poor quality tissues, tumour samples from 229 NSCLC patients (47 males, 182 females; mean ± SD age 60.54 ± 10.06 years, range 13 -90 years) and adjacent samples from 89 of these patients (67 males, 22 females; mean ± SD age 59.90 ± 9.57 years, range 37 -90 years) were analysed. Tissue samples from the lungs of 20 patients found to have benign or inflammatory lung disease (11 males, nine females; mean ± SD age 39.3 ± 16.7 years, range 0 -80 years) were used as controls. Most of the control group patients comprised patients with inflammatory lung disease.
CLINICAL PARAMETERS ASSOCIATED WITH AKR1B10 MRNA EXPRESSION
Tissue type
Relative expression of AKR1B10 mRNA (mean ± SD) was 3.5 ± 7.6 in NSCLC tissue samples, 0.4 ± 2.7 in adjacent non-AKR1B10 as a prognostic biomarker for NSCLC malignant samples and 0.6 ± 1.9 in the 20 benign lung disease control samples (Fig. 1) . AKR1B10 mRNA expression was significantly higher in tumour samples than in adjacent tissue (P = 0.003) or benign lung disease tissue (P = 0.0003). There was no statistically significant difference in AKR1B10 mRNA expression between adjacent tissue and control samples.
Age
Expression of AKR1B10 mRNA in NSCLC tumours was significantly higher than in adjacent tissue at all ages (mean ± SD, < 50 years, 4.96 ± 9.03 versus 0.04 ± 0.14, P = 0.004; 50 -60 years, 3.11 ± 5.85 versus 0.23 ± 1.19, P = 0.0004; 60 -70 years, 4.23 ± 9.15 versus 0.68 ± 4.06, P = 0.0023; > 70 years, 0.79 ± 2.06 versus 0.003 ± 0.004, P = 0.0284). No correlation was found, however, between AKR1B10 mRNA expression and increase in age. Analysis of adjacent tissue and control samples showed that they were similar in their expression of AKR1B10 mRNA at all the ages studied, with the exception of the 60 -70-year age group (mean ± SD, < 50 years, 0.04 ± 0.14 versus 0.08 ± 2.3; 50 -60 years, 0.23 ± 1.19 versus 0.01 ± 0.05; 60 -70 years, 0.68 ± 4.06 versus 0.02 ± 0.01, P = 0.0023; > 70 years, 0.003 ± 0.004 versus 0.018 ± 0.01).
Gender and smoking
Correlations were observed between AKR1B10 mRNA expression and gender and smoking. Across the whole study population, expression of AKR1B10 mRNA was significantly higher in men than in women (mean ± SD, males 3.3 ± 7.5 versus females 0.2 ± 0.6, P < 0.0001) and in smokers than in those who had never smoked (mean ± SD, smokers 3.2 ± 7.1 versus never smoked 1.2 ± 5.8, P = 0.0099). Expression of AKR1B10 mRNA was also significantly higher in smokers with NSCLC than in NSCLC patients who had never smoked (mean ± SD, smokers 4.1 ± 7.8 versus never smoked 1.7 ± 6.9, P < 0.0302) ( Table 1) .
Tumour cell type
Expression of AKR1B10 mRNA differed For squamous cell carcinoma tissues, AKR1B10 mRNA expression levels were significantly higher than for the adjacent tissues and control samples (P < 0.0001). For adenocarcinoma, the mean expression level was not statistically significantly different from that in non-malignant tissue (Table 1) .
Cell differentiation
Cell differentiation data were missing for 16 NSCLC patients, so AKR1B10 mRNA expression in 213 tissue samples (97 adenocarcinoma and 116 squamous cell carcinoma) was evaluated and a correlation was seen between raised AKR1B10 mRNA expression and cell differentiation in NSCLC.
In patients with well-differentiated tumours, expression of AKR1B10 mRNA was significantly lower in squamous cell carcinoma (P = 0.008) and in adenocarcinoma (P = 0.0251) than in those with moderately and poorly differentiated tumours (Table 2) .
Tumour size
Expression of AKR1B10 mRNA in NSCLC samples increased with increasing tumour size, however the increase was not statistically significant (Table 3) .
Other tumour characteristics
No significant associations were found between AKR1B10 mRNA expression and any other tumour characteristic (lymph node involvement, primary tumour stage and recurrence status) (data not shown).
Discussion
AKR1B10 is a nicotinamide adenine dinucleotide phosphate-dependent aldo-keto reductase 5, 17, 18 and increased concentrations have been reported in several studies of human hepatocellular carcinoma. 6, 7, 10, 19, 20 We reported previously that AKR1B10 had potential as a diagnostic marker for NSCLC when assessed in bioinformatic analyses of publicly available gene expression data. 4 The present study has now shown that AKR1B10 mRNA is over-expressed in squamous cell NSCLC compared with adjacent non-malignant tissue or tissue from benign lung disease and that expression does not differ between adjacent and benign disease tissue. Smoking status and male gender were the features that correlated particularly strongly with AKR1B10 overexpression. How raised AKR1B10 mRNA expression levels affect NSCLC, however, remains unclear.
Expression of AKR1B10 mRNA was also found to be higher in moderately and poorly differentiated tumours than in welldifferentiated tumours in the present study. In general, AKR1B10 and other aldo-keto reductases catalyse retinol-retinaldehyde conversions, 13 which is the essential first step AKR1B10 mRNA expression measured as mean ± SD relative to glyceraldehyde phosphate dehydrogenase (GAPDH) as the internal control gene. The increase in expression of AKR1B10 mRNA with increasing tumour size was not statistically significant (P > 0.05).
• Received for publication 7 August 2010 • Accepted subject to revision 23 September 2010
• Revised accepted 8 February 2011 Copyright © 2011 Field House Publishing LLP in retinoic acid synthesis. 24 Retinoic acid is involved in a large number of biological processes, including fetal development, cell proliferation and differentiation, and the control of multiple gene expression. 15 Changes in AKR1B10 expression in NSCLC might, therefore, affect the retinoic acid synthesis pathway and, consequently, tumour differentiation in NSCLC.
An association between the downregulation of AKR1B10 protein and the inhibition of tumour-cell proliferation has been previously reported. 9 Silencing of the AKR1B10 gene has been shown to result in growth inhibition in colorectal cancer cell lines 23 and, therefore, AKR1B10 expression seems to be related to tumour growth. The present study suggested that AKR1B10 expression increases with increasing tumour size, although no statistically significant correlation was found.
In summary, AKR1B10 mRNA expression was increased in NSCLC tumour tissues compared with adjacent normal tissue and control samples. In addition, patients with a positive smoking status had increased levels of AKR1B10 mRNA expression, especially in the NSCLC patients. Expression of AKR1B10 mRNA was also increased in the male gender and with moderate and poor tumour cell differentiation, and expression differed according to tumour cell type. It seems that AKR1B10 may have potential as a prognostic marker for NSCLC and this warrants further investigation.
